Proton pump inhibitor: Clinical Trials

11 trials of Proton pump inhibitor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 unknown, 1 recruiting, 1 terminated. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 7, Unknown 2, Recruiting 1, Terminated 1

Follow Proton pump inhibitor: new trials by email Literature Review of Proton pump inhibitor trials Research Report on Proton pump inhibitor

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial
Placebo, Esomeprazole 20mg - Liver Cirrhosis
Phase 4RecruitingUniversitätsklinikum Hamburg-Eppendorf4762021-04-222025-04-24
Implementation of PPI Medication PGX Testing
Genotype Guided PPI Dosing - Gastroesophageal Reflux
Phase 4CompletedNemours Children's Clinic282016-07-212018-11-21
Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication
Lansoprazole, Bismuth Potassium Citrate, Amoxicillin - Dyspepsia, Peptic Ulcer
Phase 4CompletedShanghai Jiao Tong University School of Medicine2152014-07-012015-02-03
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
Lansoprazole, Bismuth Potassium Citrate, Metronidazole - Helicobacter Pylori Treatment Failure
Phase 4CompletedShanghai Jiao Tong University School of Medicine3122014-07-012016-03-01
PPI's and SSRI's Therapy for the Management of NCCP
Citalopram - Chest Pain Rule Out Myocardial Infarction
Phase 4TerminatedEvangelismos Hospital602014-03-012019-12-02
Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
Proton pump inhibitor, Bismuth subsalicylate, Metronidazole - Cure Rate of Helicobacter Pylori Infection
Phase 4CompletedShanghai Jiao Tong University School of Medicine2002012-11-012014-08-29
Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
Esomeprazole, Amoxicillin, Clarithromycin - Functional Dyspepsia, Peptic Ulcer
Phase 4CompletedShanghai Jiao Tong University School of Medicine1802012-08-012013-06-04
Empirical Rescue Therapies of Helicobacter Pylori Infection
Proton Pump Inhibitor, Bismuth, Metronidazole - Functional Dyspepsia, Scarred Peptic Ulcer
Phase 4CompletedShanghai Jiao Tong University School of Medicine4242012-07-012013-06-04
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
Bismuth, Lansoprazole, Levofloxacin - Functional Dyspepsia, Peptic Ulcer
Phase 4CompletedShanghai Jiao Tong University School of Medicine1612012-05-012012-12-13
Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy
dexlansoprazole - Laryngopharyngeal Reflux, Hypertrophy of Lingual Tonsil
Phase 4UnknownAdvanced Center for Specialty Care802011-06-012011-04-05
Prevention of Esophageal Variceal Rebleeding
terlipressin (vasoconstrictor), pantoloc (proton pump inhibitor) - Esophageal Variceal Rebleeding
Phase 4UnknownNational Science and Technology Council, Taiwan1202006-12-012009-03-18

Conditions studied

Peptic Ulcer (3)  ·  Gastroesophageal Reflux (2)  ·  Dyspepsia (1)  ·  Fibrosis (1)  ·  Laryngopharyngeal Reflux (1)  ·  Liver Cirrhosis (1)

Sponsors

Shanghai Jiao Tong University School of Medicine (6)  ·  Advanced Center for Specialty Care (1)  ·  Evangelismos Hospital (1)  ·  National Science and Technology Council, Taiwan (1)  ·  Nemours Children's Clinic (1)  ·  Universitätsklinikum Hamburg-Eppendorf (1)

Countries

China (6)  ·  United States (2)  ·  Germany (1)  ·  Greece (1)

Top investigators

Hong Lu, M.D. (3)  ·  Ansgar W Lohse, MD (1)  ·  Hong Lu (1)  ·  James P Franciosi, MD (1)  ·  Johannes Kluwe, MD (1)  ·  Michael Friedman, MD (1)  ·  Ninos J Joseph, BS (1)

Results publications

PMID 23376004, PMID 26338726

NIH funding

2019 (1), 2023 (1)